Fulcrum Therapeutics, Inc.’s EPS Growth at a glance
Fulcrum Therapeutics, Inc. reports eps growth of 89.9% for Dec 2024. The prior period recorded 32.3% (Dec 2023). Year over year the metric moved +57.6 pts (+178.1%). The rolling three-period average stands at 38.8%. Data last refreshed Dec 7, 2025, 2:47 AM.
Latest reading
89.9% · Dec 2024
YoY movement
+57.6 pts (+178.1%)
Rolling average
38.8%
Current EPS Growth
89.9%
+57.6 pts
+178.1%
Rolling average
38.8%
Latest Value
89.9%
Dec 2024
YoY Change
+57.6 pts
Absolute
YoY Change %
+178.1%
Rate of change
3-Period Avg
38.8%
Smoothed
Narrative signal
Fulcrum Therapeutics, Inc.’s eps growth stands at 89.9% for Dec 2024. Year-over-year, the metric shifted by +57.6 pts, translating into a +178.1% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How eps growth shapes Fulcrum Therapeutics, Inc.'s story
As of Dec 2024, Fulcrum Therapeutics, Inc. reports eps growth of 89.9%. Review EPS trajectory, compounding pace, and earnings momentum supported by trailing annual filings.
Understanding EPS momentum
Sustained positive EPS growth underpins long-term shareholder returns. Volatility often reflects cyclical businesses or share-count changes.
Check the drivers behind EPS
Analyze revenue growth, margin expansion, and buybacks to see which levers are powering EPS gains.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
98%
Operating Margin
-27.4%
Net Profit Margin
-12.2%
Return on Equity
-4%
Return on Assets
-3.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Fulcrum Therapeutics, Inc. (FULC) FAQs
Answers tailored to Fulcrum Therapeutics, Inc.’s eps growth profile using the latest Financial Modeling Prep data.
What is Fulcrum Therapeutics, Inc.'s current eps growth?
As of Dec 2024, Fulcrum Therapeutics, Inc. reports eps growth of 89.9%. This reading reflects the latest filings and price data for FULC.
How is Fulcrum Therapeutics, Inc.'s eps growth trending year over year?
Year-over-year, the figure shifts by +57.6 pts (+178.1%). Pair this context with revenue growth and free cash flow signals to gauge momentum for FULC.
Why does eps growth matter for Fulcrum Therapeutics, Inc.?
Earnings-per-share growth reveals how quickly per-share net income is expanding or contracting versus the prior year. For Fulcrum Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Fulcrum Therapeutics, Inc.'s eps growth above its recent average?
Fulcrum Therapeutics, Inc.'s rolling three-period average sits at 38.8%. Comparing the latest reading of 89.9% to that baseline highlights whether momentum is building or fading for FULC.
How frequently is Fulcrum Therapeutics, Inc.'s eps growth refreshed?
Data for FULC was last refreshed on Dec 7, 2025, 2:47 AM and updates automatically every 24 hours, keeping your valuation inputs current.